<?xml version="1.0" encoding="UTF-8"?>
<fig id="f0020">
 <label>Fig. 4</label>
 <caption>
  <p>Plague case study summary. The total number of bottlenecks is reduced due to the use of a live bacterial vector system being exploited as a platform technology. Plague antigens are already known and well characterised, thus, many of the bottlenecks shift to clinical development and testing of the vaccine candidate.</p>
 </caption>
 <graphic xlink:href="gr4_lrg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
